Volume : 10, Issue : 12, December – 2023
Title:
A NEW ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF DOLUTEGRAVIR АND RILPIVIRINE IN A BULK AND TABLET BY RP-HPLC
Authors :
Busra.Komala*, Dr.D.Naresh, Dr.G.Vijay Kumar ,B.Sravanthi
Abstract :
A new, simple, precise, accurate and reproducible RP-HPLC method for Simultaneous estimation of Dolutegravir and Rilpivirine in bulk and pharmaceutical formulations. Separation of Dolutegravir and Rilpivirine was successfully achieved on a Phenomenex Luna C18 (4.6×250mm, 5µm) particle size or equivalent in an isocratic mode utilizing Acetonitrile: Phosphate Buffer (pH-4.6) (45:55 v/v) at a flow rate of 1.0mL/min and elutes was monitored at 245nm, with a retention time of 2.102 and 3.537 minutes for Dolutegravir and Rilpivirine respectively. The method was validated and the response was found to be linear in the drug concentration range of 6µg/mL to 14µg/mL for Dolutegravir and 18µg/mL to 42µg/mL for Rilpivirine. The values of the slope and the correlation coefficient were found to be 77824 and 0.999 for Dolutegravir and 10515 and 0.999 for Rilpivirine respectively. The LOD and LOQ for Dolutegravir were found to be 0.6µg/mL and 1.8µg/mL respectively. The LOD and LOQ for Rilpivirine were found to be 0.8 µg/mL and 2.4µg/mL respectively. This method was found to be good percentage recovery for Dolutegravir and Rilpivirine were found to be 100.351 and 100.93 respectively indicates that the proposed method is highly accurate. The specificity of the method shows good correlation between retention times of standard with the sample so, the method specifically determines the analytes in the sample without interference from excipients of tablet dosage forms. The method was extensively validated according to ICH guidelines for Linearity, Range, Accuracy, Precision, Specificity and Robustness.
Keywords: Dolutegravir and Rilpivirine, RP-HPLC, Accuracy, Precision, ICH Guidelines.
Cite This Article:
Please cite this article in press Busra.Komala et al, A New Analytical Method Development And Validation For Estimation Of Dolutegravir Аnd Rilpivirine In A Bulk And Tablet By RP-HPLC , Indo Am. J. P. Sci, 2023; 10 (12).
Number of Downloads : 10
References:
1. Dr. Kealey and P.J Haines, Analytical Chemistry, 1stedition, Bios Publisher, (2002), PP 1-7.
2. A.BraithWait and F.J.Smith, Chromatographic Methods, 5thedition, Kluwer Academic Publisher, (1996), PP 1-2.
3. Andrea Weston and Phyllisr. Brown, HPLC Principle and Practice, 1st edition, Academic press, (1997), PP 24-37.
4. Yuri Kazakevich and Rosario Lobrutto, HPLC for Pharmaceutical Scientists, 1stedition, Wiley Interscience A JohnWiley & Sons, Inc., Publication, (2007), PP 15-23.
5. Chromatography, (online). URL:http://en.wikipedia.org/wiki/Chromatography.
6. Meyer V.R. Practical High-Performance Liquid Chromatography, 4th Ed. England, John Wiley & Sons Ltd, (2004), PP 7-8.
7. Sahajwalla CG a new drug development, vol 141, Marcel Dekker Inc., New York, (2004), PP 421–426.
8. D. H. Shewiy, E. Kaale, P. G. Risha, B. Dejaegher, J. S. Verbeke, Y. V. Heyden, Journal Pharmaceut. Biomed. Anal, 66, 2012, 11-23.
9. M. D. Rockville, General Tests, Chapter 621 – Chromatography System Suitability, United States Pharmacopeial Convention (USP), USP 31, 2009.
10. FDA Guidance for Industry-Analytical Procedures and Method Validation, Chemistry, Manufacturing, and Controls Documentation, Centre for Drug Evaluation and Research (CDER) and Centre for Biologics Evaluation and Research (CBER), 2000.
11. Korany MA, Mahgoub H, Ossama TF, Hadir MM. Application of artificial neural networks for response surface modelling in HPLC method development. J Adv Res, 3, 2012, 53-63.
12. Swartz ME, Jone MD, Fowler P, Andrew MA. Automated HPLC method development and transfer. Lc Gc N. Am, 75, 2002, 49-50.
13. Snyder LR, Kirkland JJ, Glajach JL. X. In Practical HPLC Methods Development. John Wiley, New York, 295, 1997, 643-712.
14. Swartz M, Murphy MB. New Fronties in Chromatography. Am Lab, 37, 2005, 22-27.
15. Dolan JW. Peak tailing and resolution. Lc Gc N. Am, 20, 2002, 430-436.